Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma
DOI:
https://doi.org/10.12928/pharmaciana.v13i2.24638Keywords:
VEGFR inhibitors, renal cell carcinoma, kidney cancer, progression-free survival, adverse drug eventsAbstract
Vascular endothelial growth factors receptors (VEGFR) inhibitors play a vital role in the treatment of renal cell carcinoma. These are small molecules that predominantly exhibit anti-angiogenesis activity in conjunction with other anti-tumor effects. These drug therapies are approved for the use in patients as frontline agents or adjuvant therapy in renal cell carcinoma. However, VEGFR inhibitors are associated with undesirable adverse events, with some having a more manageable toxicity profile compared to others. As a result, choice of treatment poses a challenge for healthcare providers and patients. Nonetheless, these agents demonstrate improved disease/progression free survival (DFS/PFS) values and remain a critical component in the treatment of kidney cancer.
Downloads
Published
Issue
Section
License
Authors who publish with Pharmaciana agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
1.png)
